Skip to main content

Table 2 Changes in the metabolic and cardiovascular profile during PI-therapy

From: Changes in lipid profiles after switching to a protease inhibitor-containing cART - unfavourable effect of fosamprenavir in obese patients

PI group   ATV/r FPV/r SQV/r p-valuea
Characteristic      
Number of patients   84 23 17  
Serum cholesterol
    at baseline [mg/dl] Median 204 179 173  
  (IQR) (159; 251) (148; 217) (143; 221) 0.19
    at month 6 [mg/dl] Median 186 204 209  
  (IQR) (157; 228) (177; 284) (164; 278) 0.055
    relative change at month 6 % (Median) -6 +21 +8 0.0002
Serum triglycerides
    at baseline [mg/dl] Median 187 136 205  
  (IQR) (113; 334) (87; 289) (143; 366) 0.20
    at month 6 [mg/dl] Median 186 169 218  
  (IQR) (119; 280) (122; 239) (120; 342) 0.90
Serum glucose
    at baseline [mg/dl] Median 90 87 89  
  (IQR) (82; 101) (83; 97) (78; 99) 0.70
    at month 6 [mg/dl] Median 91 90 97  
  (IQR) (83; 101) (83; 103) (89; 118) 0.17
High cardiovascular risk b
    at baseline n (%) 23 (27) 2 (9) 2 (12) 0.088
    at month 6 n (%) 20 (24) 3 (13) 3 (18) 0.50
  1. a: Kruskal-Wallis-H-test for metric variables; p-value for inter-group comparisons
  2. b: risk of developing a fatal cardiovascular event over the next ten years >5%, according to the HeartScore [2, 3, 53]